CIK 0001759186 · Non-accelerated filer<br>Smaller reporting company
Z Squared Inc.
Sign in to watch- Ticker
- ZSQR
- Exchange
- Nasdaq
- Industry
- Finance Services
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 981465952
- Phone
- 954-400-9994
- Business address
- 550 SOUTH ANDREWS AVE., STE #700, FORT LAUDERDALE, FL, 33301
- Former names
- Coeptis Therapeutics Holdings, Inc., Bull Horn Holdings Corp.
- Open-market buys, last 90 days
- $7,840
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$7,840. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-12 | DeSilva Tara Director | Purchase | +1,800 | $0.58 | $1K | 32,266 |
| 2024-01-10 | Cogley Brian Chief Financial Officer | Purchase | +5,000 | $0.67 | $3K | 30,000 |
| 2024-01-08 | Mehalick David CEO and President | Purchase | +6,000 | $0.67 | $4K | 2,768,611 |
| 2024-01-08 | Mehalick David CEO and President | Purchase | +14,004 | $0.66 | $9K | 2,782,615 |
| 2024-01-05 | Yerace Daniel Alexander VP of Operations | Purchase | +10,850 | $0.69 | $7K | 1,071,455 |
| 2024-01-05 | Salkind Gene Director | Purchase | +11,600 | $0.69 | $8K | 284,056 |
| 2024-01-05 | Mehalick David CEO and President | Purchase | +5,050 | $0.69 | $3K | 2,762,611 |
| 2024-01-05 | Cochran Christopher P. Director | Purchase | +7,000 | $0.77 | $5K | 37,000 |
| 2023-12-07 | Mehalick David CEO and President | Gift | −700,000 | 2,757,561 | ||
| 2023-08-29 | Salkind Gene Director | Purchase | +4,006 | $1.01 | $4K | 4,046 |
| 2023-08-25 | Salkind Gene Director | Purchase | +28,638 | $0.91 | $26K | 28,638 |
| 2023-08-23 | Calise Chris Director | Purchase | +9,000 | $0.94 | $8K | 1,462,315 |
| 2023-08-23 | Calise Chris Director | Purchase | +2,582 | $0.94 | $2K | 1,464,897 |
| 2023-01-27 | Yerace Daniel Alexander VP of Operations | Grant or award · Incentive Stock Options (right to buy) | +200,000 | 200,000 | ||
| 2023-01-27 | Sheehy Christine Elise CFO and Secretary | Grant or award · Incentive Stock Options (right to buy) | +200,000 | 200,000 | ||
| 2023-01-27 | Salkind Gene Director | Grant or award · Non-qualified Stock Options (right to buy) | +30,000 | 30,000 | ||
| 2023-01-27 | Mehalick David CEO and President | Grant or award · Non-qualified Stock Options (right to buy) | +375,000 | 375,000 | ||
| 2023-01-27 | Mehalick David CEO and President | Grant or award · Incentive Stock Options (right to buy) | +250,000 | 250,000 | ||
| 2023-01-27 | DeSilva Tara Director | Grant or award · Non-qualified Stock Options (right to buy) | +30,000 | 30,000 | ||
| 2023-01-27 | Deschamps Philippe Director | Grant or award · Non-qualified Stock Options (right to buy) | +30,000 | 30,000 |
Page 6 of 7 · 129 trades